Login to Your Account



Immungene Looks East for $9M Series A

By Marie Powers
Staff Writer

Friday, November 8, 2013

Immungene Inc. landed a $9 million Series A round from Ally Bridge Group, a health care investment firm with offices in Hong Kong and the U.S., to advance its antibody-cytokine fusion technology platform targeting cancer therapies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription